A clinical study demonstrated that the STAT3 target genes PIM1, B-cell leukemia-3 (BCL3), and SOCS3 in peripheral blood CD4+ T cells from treatment-naïve RA patients show the strongest differential regulation, with each gene’s expression highly associated with paired intracellular phospho-STAT3 (5). This evidence concerns the gene CD4 and rheumatoid arthritis.